Heberprot-P benefits thousands of patients

More than 300,000 patients from 26 countries have benefited in the last 10 years from Heberprot-P, the only product in the world for complex diabetic foot ulcers that shows remarkable results and it prevents amputation in most cases.

Doctor in Sciences Manuel Raíces, researcher at the Center for Genetic Engineering and Biotechnology, the institution that developed the new drug, explained that in 2018 more than 12,000 Cuban patients were treated with Heberprot-P.

This maintained the expectation of the impact of the therapy by reducing the relative risk of amputation by about 71 percent, which results in more than 17 thousand amputations avoided, said the eminent scientist.

Heberprot-P is registered in more than twenty states such as Venezuela, Slovakia and Mexico, where diabetes is the leading cause of death.

(Taken from Radio Reloj in Spanish)

Written by Radio Grito de Baire